Department of Surgery, Nagasaki University Graduate School of Biomedical Science, Nagasaki, Japan
Department of Surgery, National Hospital Organization Nagasaki Medical Center, Nagasaki, Japan.
Anticancer Res. 2020 Apr;40(4):2303-2309. doi: 10.21873/anticanres.14196.
BACKGROUND/AIM: To predict pCR during neoadjuvant chemotherapy is still difficult. The aim of this study was to evaluate the optimal tumor reduction rate and modalities for predicting pCR after two cycles of docetaxel.
We analyzed 52 patients with HER2-positive or triple-negative breast cancer. The tumor reduction rate was evaluated after two 3-week cycles of docetaxel (plus trastuzumab for HER2-positive cancer patients). Patients without progression completed two additional cycles of docetaxel and four cycles of an anthracycline-containing regimen.
Twenty-eight patients achieved pCR. The optimal tumor reduction rates for predicting pCR were 23, 39, 32, and 40% for US, caliper, MMG, and MRI measurements, respectively. The AUC was highest for caliper measurements. The optimal modality for predicting pCR differed among subtypes.
Although tumor reduction rate after two cycles of chemotherapy is highly predictive of pCR, the optimal cutoff value differed among the modalities and breast cancer subtype.
背景/目的：预测新辅助化疗中的病理完全缓解（pCR）仍然具有挑战性。本研究旨在评估在接受两个周期多西他赛治疗后，预测 pCR 的最佳肿瘤退缩率和模式。
我们分析了 52 例 HER2 阳性或三阴性乳腺癌患者。在接受两个 3 周周期多西他赛（HER2 阳性癌症患者加曲妥珠单抗）治疗后，评估肿瘤退缩率。没有进展的患者完成了两个周期多西他赛和四个周期含蒽环类药物的方案。
28 例患者达到 pCR。预测 pCR 的最佳肿瘤退缩率分别为超声、卡尺、MMG 和 MRI 测量的 23%、39%、32%和 40%。卡尺测量的 AUC 最高。预测 pCR 的最佳模式在不同亚型之间存在差异。
尽管两个周期化疗后的肿瘤退缩率高度预测 pCR，但最佳截断值在不同模式和乳腺癌亚型之间存在差异。
